List of Excipients in Branded Drug RHOGAM ULTRA-FILTERED PLUS

RhoGAM Ultra-Filtered PLUS Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

RhoGAM Ultra-Filtered PLUS is a human plasma-derived Rho(D) immune globulin indicated to prevent Rh immunization in Rh-negative patients exposed to Rh-positive red blood cells. Its commercial value depends primarily on anti-D potency, viral-safety controls, plasma sourcing, manufacturing capacity, and clinical familiarity. Excipients support product stability and administration but are unlikely to create a strong standalone exclusivity position.

The principal excipient strategy is conservative: use a low-complexity formulation with glycine as a stabilizer and polysorbate 80 as a surfactant, while maintaining a refrigerated liquid presentation. The most credible commercial opportunities are improved delivery systems, reduced injection burden, room-temperature stability, supply diversification, and next-generation anti-D products rather than substitution of excipients alone.

What is RhoGAM Ultra-Filtered PLUS?

RhoGAM Ultra-Filtered PLUS is an intramuscular human Rho(D) immune globulin manufactured by Kedrion Biopharma. The product contains anti-Rho(D) antibodies collected from screened human plasma donors and purified through a manufacturing process that includes ultrafiltration and viral-reduction controls.

The product is used in Rh-negative women and other Rh-negative individuals after exposure to Rh-positive red blood cells. Common indications include:

• Antepartum prophylaxis at approximately 28 weeks of gestation.
• Postpartum prophylaxis when the newborn is Rh-positive or Rh status is unknown.
• Pregnancy termination, miscarriage, ectopic pregnancy, or invasive obstetric procedures.
• Transfusion exposure involving Rh-positive red blood cells or blood products.

The standard RhoGAM dose is 300 micrograms, equivalent to 1,500 international units, administered intramuscularly. A smaller 50-microgram presentation, MICRhoGAM, is used for selected early-pregnancy exposures under the prescribing information. [1]

What are the active ingredient and dosage forms?

Attribute	RhoGAM Ultra-FILTERED PLUS
Active ingredient	Human Rho(D) immune globulin
Biological class	Plasma-derived polyclonal IgG
Primary route	Intramuscular injection
Standard dose	300 micrograms or 1,500 IU
Early-exposure dose	50 micrograms or 250 IU in the MICRhoGAM presentation
Presentation	Sterile liquid injection, supplied with prefilled syringe and needle configurations depending on package
Storage	Refrigerated, generally 2°C to 8°C
Therapeutic purpose	Prevention of Rh(D) alloimmunization
FDA regulatory category	Licensed biological product

What excipients are used in RhoGAM Ultra-FILTERED PLUS?

The RhoGAM formulation uses a limited excipient system. The U.S. prescribing information identifies glycine and polysorbate 80 among the inactive ingredients. The product does not use preservatives. [1]

Excipient	Formulation role	Commercial relevance
Glycine	Stabilizer and tonicity-supporting excipient	Helps preserve antibody integrity during refrigerated storage
Polysorbate 80	Surfactant	Reduces surface adsorption and aggregation during processing and storage
Water for injection	Vehicle	Provides the liquid delivery medium
No preservative	Avoids multidose preservative exposure	Supports single-dose parenteral use

The formulation is consistent with established immunoglobulin practice. Glycine is widely used in antibody products because it can support protein stability without introducing a complex buffer system. Polysorbate 80 is used in biologics to reduce interfacial stress caused by contact with containers, syringes, air-liquid interfaces, and manufacturing equipment.

The exact commercial opportunity is therefore not based on discovering a new excipient. It is based on optimizing concentration, grade, degradation control, container compatibility, and process conditions without reducing anti-D potency.

How does the excipient strategy affect product quality?

Excipient performance is directly tied to product quality attributes for a plasma-derived antibody product.

Antibody aggregation

IgG aggregation can reduce potency, increase immunogenicity concerns, and create problems in filtration or injection. Polysorbate 80 can reduce aggregation caused by agitation and contact with hydrophobic surfaces. Its degradation must be controlled because oxidized or hydrolyzed surfactant can lose protective performance.

Interfacial stress

RhoGAM is supplied as a liquid injectable. During filling, shipping, syringe handling, and administration, the antibody encounters air-liquid and container-liquid interfaces. A surfactant reduces antibody adsorption and denaturation at those interfaces.

Protein stability

Glycine supports the protein environment during refrigerated storage. The formulation does not appear to rely on a highly complex buffering system. This can simplify manufacturing, but the product remains dependent on cold-chain control.

Particles and subvisible aggregates

Parenteral immunoglobulins require control of visible and subvisible particles. Surfactant quality, filtration conditions, filling-line agitation, and container closure performance affect this profile. A formulation change involving polysorbate 80 would require evaluation of particle burden, oxidation, hydrolysis, extractables, and container interaction.

What formulations are protected by patents?

Public FDA labeling identifies the formulation composition and manufacturing information required for safe use, but it does not establish a broad, commercially enforceable patent position for the excipient combination itself. Biologic products often rely on a combination of:

• Biological-license protection.
• Trade secrets covering plasma pooling, fractionation, purification, viral reduction, and analytical release testing.
• Process know-how.
• Supplier qualification and plasma collection infrastructure.
• Trademark and product recognition.
• Product-specific patents, where available.

RhoGAM is not an ordinary small-molecule prescription product listed in the FDA Orange Book. Biologics are generally tracked through the Purple Book and FDA biologics licensing records rather than Orange Book patent listings. [2,3]

A potential competitor would therefore need to conduct a current patent and regulatory review covering:

1. Anti-D immunoglobulin composition claims.
2. Fractionation and ultrafiltration processes.
3. Viral inactivation and clearance methods.
4. Stabilized liquid immunoglobulin formulations.
5. Prefilled syringe and needle configurations.
6. Methods for preventing Rh(D) alloimmunization.
7. Manufacturing cell, plasma, and donor-screening controls.
8. Product-specific labeling and exclusivity records.

The strongest barriers are likely process and supply barriers rather than the use of glycine or polysorbate 80 as generic excipients.

When does RhoGAM lose exclusivity?

RhoGAM does not have a single small-molecule patent cliff comparable to a conventional tablet drug. Its market position is governed by biologic licensing, manufacturing know-how, product quality, donor-plasma access, and the regulatory pathway for competing immune globulin products.

The practical exclusivity framework is:

Protection layer	Relevance to RhoGAM
Orange Book patent listing	Generally not the primary mechanism because RhoGAM is a biologic
Biologic license	Establishes regulatory approval for the licensed product
Reference-product exclusivity	May apply under the Public Health Service Act and BPCIA framework, depending on the product and reference designation
Process trade secrets	Potentially significant
Plasma supply	Major operational barrier
Trademark	Protects RhoGAM branding but not the underlying therapy
Clinical and commercial familiarity	Supports prescriber and hospital retention

The FDA approved RhoGAM before the modern BPCIA framework. The existence and duration of any applicable reference-product exclusivity must be determined from current FDA records and the product’s regulatory history, not inferred from a conventional patent expiration date.

What is the FDA regulatory status of RhoGAM Ultra-FILTERED PLUS?

RhoGAM Ultra-FILTERED PLUS is an FDA-licensed biologic used for prevention of Rh(D) alloimmunization. Its label establishes the approved indications, dosing, contraindications, warnings, storage conditions, and administration requirements. [1]

The relevant regulatory risks include:

• Variability in anti-D potency between lots.
• Immunoglobulin aggregation and particulate matter.
• Viral safety and emerging pathogen controls.
• Plasma donor availability.
• Incorrect dosing after large fetomaternal hemorrhage.
• Product substitution without confirming dose equivalence and administration route.
• Supply interruptions affecting obstetric hospitals.

Because Rho(D) immune globulin is a biological product derived from human plasma, manufacturing changes can require substantial comparability work. A change to polysorbate 80 grade, glycine concentration, container closure, or filling process could affect stability and may require regulatory filing and supporting studies.

Are there biosimilar or generic risks for RhoGAM?

A conventional generic pathway is not appropriate for RhoGAM because it is a biologic. A biosimilar or follow-on product would need to demonstrate a high degree of similarity to the reference product, with no clinically meaningful differences in safety, purity, and potency under the applicable FDA pathway. [4]

The competitive risk is limited by several technical factors:

Polyclonal composition

RhoGAM contains a polyclonal antibody population. Competitors must reproduce the relevant anti-D activity and potency profile rather than match a single monoclonal antibody sequence.

Plasma dependence

A competing plasma-derived product requires access to suitable Rh-negative or immunized donors, validated collection systems, sufficient plasma volume, and long-term supply planning.

Potency and assay comparability

Anti-D activity requires validated potency testing. Differences in assay methods, reference standards, antibody specificity, and lot consistency can complicate direct comparison.

Clinical substitution

Even if a competitor is approved, automatic substitution rules may differ from those for small-molecule generics. Hospitals may evaluate inventory, dosing, administration, safety records, and reimbursement before switching.

The most credible near-term threat is therefore a competing licensed Rho(D) immune globulin product, not an excipient-driven generic launch.

Which companies compete with RhoGAM?

The U.S. market includes products from multiple suppliers of Rho(D) immune globulin or related anti-D products. Known competitive products include:

Product	Company or historical sponsor	Key competitive dimension
RhoGAM Ultra-FILTERED PLUS	Kedrion Biopharma	Established obstetric brand and broad clinical familiarity
MICRhoGAM	Kedrion Biopharma	Lower-dose presentation for early pregnancy exposure
Rhophylac	CSL Behring	Competing anti-D immunoglobulin with intravenous and intramuscular administration options in applicable markets
WinRho SDF	Sobi	Anti-D immune globulin with additional hematologic use in selected indications

Product availability, labeling, manufacturing status, and market participation can change over time. Competitive analysis should separate obstetric prophylaxis from hematology indications because dosing, route, customer base, and reimbursement differ.

What commercial opportunities exist in excipient optimization?

Longer refrigerated shelf life

A formulation that maintains anti-D potency and limits aggregation over a longer refrigerated shelf life could reduce inventory loss. The value is highest for hospitals with variable delivery volumes and for distributors serving geographically dispersed customers.

Improved temperature excursion tolerance

A product with validated short-term temperature excursion stability could reduce write-offs caused by shipping events. This would not necessarily eliminate refrigeration requirements, but it could improve logistics resilience.

Reduced injection volume

A higher-concentration liquid could reduce injection volume while preserving the 300-microgram dose. The opportunity is clinically relevant because intramuscular administration can be painful and may require a large-volume injection. Any concentration increase must maintain viscosity, syringeability, potency, particle control, and tolerability.

Prefilled delivery systems

A ready-to-administer prefilled syringe can reduce preparation steps and medication errors. Commercial differentiation may include:

• Needle-safety devices.
• Low-dead-volume syringes.
• Clear dose markings.
• Better grip and administration ergonomics.
• Packaging designed for obstetric and emergency department workflows.

The delivery device may be more defensible than a simple excipient change if protected by device or combination-product claims.

Polysorbate replacement

Polysorbate 80 alternatives, including other surfactants or newer protein-stabilizing excipients, could reduce risks associated with oxidation and hydrolysis. A replacement strategy would require extensive comparability work because the surfactant affects aggregation, particles, adsorption, potency, and container compatibility.

A successful replacement could support a differentiated formulation patent, but the regulatory burden would be high and the market may not reward the change unless it improves shelf life, stability, tolerability, or manufacturing yield.

Alternative dry or lyophilized presentation

A lyophilized Rho(D) immune globulin could reduce dependence on liquid-state stability and potentially improve shipping robustness. The drawbacks are reconstitution steps, administration time, added packaging, and possible dosing errors. This opportunity is less attractive if hospitals strongly prefer ready-to-use liquid syringes.

How strong is the RhoGAM patent estate?

The patent estate should be viewed as moderate to weak for basic excipient composition and stronger for manufacturing, delivery, and process know-how.

Asset category	Likely strength
Glycine and polysorbate 80 combination	Low, because both are established excipients
Generic liquid anti-D formulation	Low to moderate, depending on claim scope and prior art
Specific excipient concentrations and stability profile	Moderate if supported by robust data
Prefilled syringe or safety device	Moderate to strong if claims are well drafted
Plasma fractionation and ultrafiltration	Potentially strong, especially with narrow process parameters
Viral clearance process	Potentially strong, but dependent on claim scope and reproducibility
Anti-D potency and analytical controls	Moderate, with value primarily as know-how
Brand and hospital adoption	Commercially strong but not patent-based

The most defensible intellectual-property strategy would combine formulation claims with device, container-closure, stability, and manufacturing claims. A single patent directed to glycine and polysorbate 80 would face substantial validity and freedom-to-operate challenges.

What generic launch risks exist for RhoGAM?

A competitor could enter through several scenarios:

1. A licensed plasma-derived anti-D product with comparable obstetric labeling.
2. A biologic follow-on product supported by analytical and clinical comparability.
3. A differentiated prefilled syringe with lower injection volume.
4. A product with improved storage or temperature-excursion performance.
5. A hospital-focused product supported by supply guarantees and contracting.
6. A non-U.S. product that expands into the U.S. after regulatory approval.

The highest commercial risk would arise from a competitor combining equivalent clinical utility with better supply reliability and lower acquisition cost. Excipients alone are unlikely to drive switching. Procurement departments will place greater weight on product availability, dose accuracy, administration convenience, reimbursement, and manufacturer reliability.

How does RhoGAM compare with Rhophylac and WinRho?

Factor	RhoGAM	Rhophylac	WinRho SDF
Core therapy	Rho(D) immune globulin	Rho(D) immune globulin	Rho(D) immune globulin
Main obstetric use	Yes	Yes	Yes, subject to label and market
Plasma-derived	Yes	Yes	Yes
Primary differentiation	Brand familiarity and obstetric penetration	Competing product and route flexibility in applicable markets	Broader anti-D positioning in selected indications
Excipient opportunity	Stability, syringe, volume	Similar formulation and device opportunities	Similar formulation and manufacturing opportunities
Main barrier to entry	Plasma supply and licensed manufacturing	Same	Same
Patent-driven differentiation	Limited for basic excipients	Likely limited for basic excipients	Likely limited for basic excipients

The commercial comparison should focus on label breadth, route of administration, supply consistency, hospital contracting, inventory management, and product presentation. Basic excipient composition is unlikely to determine market share.

What licensing opportunities exist?

Licensing opportunities are most attractive in four areas:

Stabilized liquid immunoglobulin platforms

A platform that improves IgG stability with lower surfactant degradation could be licensed across multiple immune globulin products. The value would increase if the platform supports room-temperature excursion claims or longer shelf life.

Prefilled syringe and injection technology

A device company could license a low-volume, low-dead-space, safety-engineered syringe platform for anti-D immune globulin. This opportunity has clearer product differentiation than a conventional excipient change.

Plasma and manufacturing partnerships

Regional licensing or supply agreements could address donor-plasma access, fractionation capacity, and local fill-finish requirements. These deals may be more commercially important than formulation licensing.

Recombinant or engineered anti-D alternatives

A recombinant anti-D product could reduce dependence on human plasma, but it would require a substantial development program to reproduce clinically relevant anti-D activity and establish prevention of alloimmunization. This is a long-term opportunity with high technical and regulatory risk.

What patent litigation affects RhoGAM?

No specific active patent litigation should be assumed from the product name or from the existence of competing anti-D immune globulin products. Litigation exposure must be evaluated through current federal court records, Patent Trial and Appeal Board proceedings, FDA records, and company disclosures.

For diligence purposes, the highest-value litigation questions are:

• Whether a competitor has challenged a process or formulation patent.
• Whether a product is entering under a biosimilar or other biologic pathway.
• Whether a settlement restricts launch timing.
• Whether a device supplier controls key syringe or needle-safety rights.
• Whether manufacturing know-how is subject to confidentiality or licensing restrictions.

Unlike an Orange Book-listed small molecule, RhoGAM does not present a standard Paragraph IV litigation pathway tied to an ANDA patent certification.

Key Takeaways

• RhoGAM Ultra-FILTERED PLUS uses a simple excipient system centered on glycine and polysorbate 80.
• Excipients support IgG stability, reduce interfacial damage, and help control aggregation.
• Basic excipient claims are unlikely to provide strong exclusivity because the ingredients are established in biologic formulations.
• The principal competitive barriers are plasma supply, anti-D potency, manufacturing validation, viral safety, and regulatory approval.
• RhoGAM is a biologic, so the Orange Book and conventional Paragraph IV framework are not the primary exclusivity mechanisms.
• The strongest commercial opportunities are improved prefilled syringes, lower injection volume, longer refrigerated shelf life, temperature-excursion tolerance, and supply-chain reliability.
• A next-generation formulation would need to demonstrate comparable anti-D potency, purity, aggregation profile, particle control, container compatibility, and clinical performance.
• A recombinant anti-D product could create a larger structural opportunity but would require a high-cost regulatory and clinical program.

FAQs

Can RhoGAM be reformulated without changing its regulatory status?

A formulation change involving glycine, polysorbate 80, concentration, container closure, or dosage volume would require regulatory assessment and supporting comparability data. The filing pathway would depend on the scale and impact of the change.

Does RhoGAM contain preservatives?

RhoGAM is supplied as a single-dose injectable product and does not rely on a multidose preservative system. Its listed excipients include glycine and polysorbate 80. [1]

Could a polysorbate-free Rho(D) immune globulin obtain patent protection?

Potentially, if the formulation produces a non-obvious and reproducible improvement in stability, aggregation control, potency retention, or shelf life. A claim directed only to removing polysorbate would face prior-art and enablement scrutiny.

Is room-temperature RhoGAM commercially feasible?

A room-temperature presentation would require validated stability data covering potency, aggregation, particles, sterility, container compatibility, and transport conditions. It could have substantial value in decentralized and emergency-care settings.

What is the most attractive investment area around RhoGAM?

The strongest risk-adjusted opportunities are delivery systems, manufacturing capacity, plasma-supply partnerships, and stability technologies that apply across multiple immunoglobulin products. Basic excipient substitution has a narrower commercial case.

References

1. Kedrion Biopharma Inc. (n.d.). RhoGAM Ultra-Filtered PLUS and MICRhoGAM prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product